# Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

> **NCT01107626** · PHASE3 · COMPLETED · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 1516 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Pemetrexed Disodium Heptahydrate

## Key facts

- **NCT ID:** NCT01107626
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-25
- **Primary completion:** 2019-01-31
- **Final completion:** 2021-08-17
- **Target enrollment:** 1516 (ACTUAL)
- **Last updated:** 2023-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01107626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01107626, "Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01107626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*